- Conditions
- Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Hepatocellular Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Pleural Neoplasm, Malignant Skin Neoplasm, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Thymus Neoplasm, Neuroendocrine Neoplasm, Thyroid Gland Carcinoma, Urothelial Carcinoma, Cancer of Unknown Primary Site
- Interventions
- Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography, 18F-FDG
- Procedure · Drug · Radiation
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 978
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Gynecologic Cancer, Cervical Cancer
- Interventions
- Not listed
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma
- Interventions
- Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
- Conditions
- Physical Activity, Breast Cancer, Cervical Cancer, Ovarian Cancer, Endometrial Cancer
- Interventions
- Hula
- Behavioral
- Lead sponsor
- University of Hawaii
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Cervical Cancer
- Interventions
- Sacituzumab Tirumotecan, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 686 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 38
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 35 more
- Conditions
- Cervical Cancer
- Interventions
- biopsy, computed tomography, positron emission tomography, fludeoxyglucose F 18
- Procedure · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cervical Cancer, Cervical Precancer, Adherence
- Interventions
- Not listed
- Lead sponsor
- Brookdale University Hospital Medical Center
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 3
- States / cities
- Brooklyn, New York • El Paso, Texas
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage I Cervical Cancer
- Interventions
- Isosulfan Blue, Lymph Node Mapping, Lymphangiography, Methylene Blue, Radionuclide Imaging, Sentinel Lymph Node Biopsy, Technetium Tc-99m Sulfur Colloid, Therapeutic Conventional Surgery
- Drug · Procedure · Radiation
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Uterine Cervical Neoplasms
- Interventions
- IMRT with tomotherapy
- Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
- Interventions
- VLS-1488
- Drug
- Lead sponsor
- Volastra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Newport Beach, California • Aurora, Colorado + 11 more
- Conditions
- Cervical Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific, Veno-occlusive Disease
- Interventions
- Fragmin, placebo
- Drug · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC), Squamous Cell Carcinoma of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Bladder Cancer, Uterine Cancer
- Interventions
- GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
- Biological
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • Houston, Texas
- Conditions
- Gynecologic Cancer, Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Surgery, Treatment Adherence, Quality of Life
- Interventions
- Unimodal, Trimodal
- Other
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 83 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Cervical Cancer
- Interventions
- cisplatin, vinorelbine tartrate
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 9
- States / cities
- Orange, California • Honolulu, Hawaii • Baltimore, Maryland + 6 more
- Conditions
- Cervical Cancer, Endometrial Cancer, Cervical Carcinoma
- Interventions
- Lymphatic Mapping
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Uterine Cervical Neoplasms, Endometrial Neoplasms, Anus Neoplasms, Rectal Neoplasms, Prostatic Neoplasms
- Interventions
- fluorothymidine F 18
- Drug
- Lead sponsor
- John M. Buatti
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Melanoma, Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Urothelial Carcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Microsatellite Instability High, Gastric Cancer, Esophageal Cancer
- Interventions
- Echopulse, Poly ICLC, Standard of Care PD-1 Therapy
- Device · Drug
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Urothelial Carcinoma Bladder, Squamous Cell Carcinoma
- Interventions
- VET3-TGI, Atezolizumab
- Drug
- Lead sponsor
- KaliVir Immunotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Orange, California • Miami, Florida + 4 more
- Conditions
- Breast Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer
- Interventions
- fluorouracil, pegylated liposomal doxorubicin hydrochloride, hyperthermia treatment
- Drug · Procedure
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cervical Carcinoma, Endometrial Carcinoma
- Interventions
- Hypofractionated Radiation Therapy
- Radiation
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Gynecologic Neoplasm, Brachytherapy, Therapeutic Touch, Endometrial Cancer, Cervical Cancer, Vaginal Cancer, Vulvar Cancer
- Interventions
- Reiki therapy
- Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Cervical Cancer, Precancerous Condition
- Interventions
- imiquimod, Ablative or excisional therapy
- Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2010
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 5 more
- Conditions
- Cervical Cancer
- Interventions
- gemcitabine hydrochloride
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 31 more
- Conditions
- Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
- Interventions
- tucatinib, trastuzumab, fulvestrant
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 75
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more